Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
---|
04/29/2004 | WO2004018472A3 Pyrimido compounds having antiproliferative activity |
04/29/2004 | WO2004014311A3 Nogo receptor antagonists |
04/29/2004 | WO2004012732A3 Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy |
04/29/2004 | WO2004011402A3 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |
04/29/2004 | WO2004000230A3 Cyclothiocarbamative derivatives as pr modulators and use thereof for treatment of skin disorders |
04/29/2004 | WO2003101996A8 Esters in position 20 of camptothecins |
04/29/2004 | WO2003099823A3 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
04/29/2004 | WO2003097649A3 1-oxa-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof |
04/29/2004 | WO2003093242A3 Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade |
04/29/2004 | WO2003087368A3 Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification |
04/29/2004 | WO2003087367A3 Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
04/29/2004 | WO2003075840A3 Human antibodies specific to kdr and uses thereof |
04/29/2004 | WO2003057912A3 Molecular trichogram |
04/29/2004 | WO2003042399A9 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof |
04/29/2004 | WO2003020949A3 Targeted nucleic acid constructs and uses related thereto |
04/29/2004 | WO2003015612A9 Materials and methods to promote repair of nerve tissue |
04/29/2004 | WO2003013537A9 Irinotecan for treatment of cancer |
04/29/2004 | WO2003013536A9 Methods for treatment of cancer using irinotecan based on ugt1a1 |
04/29/2004 | WO2003013535A9 Use of irinotecan for improved treatment of cancer based on mdr1 |
04/29/2004 | WO2003013534A9 Methods for the treatment of cancer with irinotecan based on cyp3a5 |
04/29/2004 | WO2003013533A9 Methods for improved treatment of cancer with irinotecan based on mrp1 |
04/29/2004 | WO2003010196A3 Variants and exons of the glyt1 transporter |
04/29/2004 | WO2003009807A3 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
04/29/2004 | WO2003003972A3 Kinetic resolution of a intermediate useful in the production of benazepril and analogues thereof |
04/29/2004 | WO2003003004A3 Method for identifying compounds the specifically deplete mast cells |
04/29/2004 | WO2002102787A3 Novel sulfonic acid derivatives |
04/29/2004 | WO2002102391A3 Composition comprising nanoparticulate spironolactone |
04/29/2004 | WO2002070669A3 Secreted proteins |
04/29/2004 | WO2002066056A8 Synthetic vaccines comprising polyhydroxypolymer carriers |
04/29/2004 | WO2002018341A8 Quinoline- (c=o) - (di-, tri- and tetrapeptide) derivatives as caspase inhibitors |
04/29/2004 | WO2001095899A8 Pharmaceutical compositions comprising cannabidiol derivatives |
04/29/2004 | US20040083447 1-Phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands |
04/29/2004 | US20040082807 Novel salt forms of poorly soluble probucol esters and ethers |
04/29/2004 | US20040082805 Cytokine antagonist; immunology, viricides, antitumor agents, anticancer agents |
04/29/2004 | US20040082790 Piperidine amides as modulators of chemokine receptor activity |
04/29/2004 | US20040082789 Thieno[2,3-c]iosquinolines for use as inhibitors of parp |
04/29/2004 | US20040082787 Chemical compounds |
04/29/2004 | US20040082781 Bicyclic nitrogenous fused-ring compound |
04/29/2004 | US20040082763 Diagnosis, therapy of Alzheimer's disease; synthetic antibody |
04/29/2004 | US20040082758 Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated |
04/29/2004 | US20040082757 Echinocandin derivatives, pharmaceutical compositions containing same and use thereof as drugs |
04/29/2004 | US20040082666 Antiserotonine agents |
04/29/2004 | US20040082664 Derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition |
04/29/2004 | US20040082663 Imidazoline receptor binding compounds |
04/29/2004 | US20040082656 Higher unsaturated fatty acid composition |
04/29/2004 | US20040082653 Using prostaglandin antagonist |
04/29/2004 | US20040082647 Anticholesterol agents; controlling bile acid transfer into intestines |
04/29/2004 | US20040082643 Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus |
04/29/2004 | US20040082642 Novel estrogen receptor ligands and method III |
04/29/2004 | US20040082640 Use of cox-2 inhibitors for preventing immunodeficiency |
04/29/2004 | US20040082638 Compounds, compositions and methods |
04/29/2004 | US20040082635 Fused cyclic compounds and medicinal use thereof |
04/29/2004 | US20040082631 Pyrazole compositions useful as inhibitors of ERK |
04/29/2004 | US20040082630 1g(a)-Amino-n-hydroxy-acetamide derivatives |
04/29/2004 | US20040082619 Pyridone derivatives having affinity for cannabinoid 2-type receptor |
04/29/2004 | US20040082617 Sulphones which modulate the action of gamma secretase |
04/29/2004 | US20040082605 Use |
04/29/2004 | US20040082603 2,3-Dihydro-isoindol-1-one derivatives |
04/29/2004 | US20040082602 Kinase inhibitor; analgesics; antiarthritic agents; antihistamines; gastrointestinal disorders |
04/29/2004 | US20040082597 Use of CRF antagonists and related compositions |
04/29/2004 | US20040082592 Metabotropic glutamate receptor antagonists |
04/29/2004 | US20040082590 Dietetics; antidiabetic agents; sexual disorders |
04/29/2004 | US20040082589 Quinoline derivatives as nk-3 and nk-2 antagonists |
04/29/2004 | US20040082584 Antiinflammatory agents; antihistamines; skin disorders; antiarthritic agents; antidiabetic agents; autoimmune disease |
04/29/2004 | US20040082583 Chemical compounds |
04/29/2004 | US20040082582 Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
04/29/2004 | US20040082576 Cardiovascular disorders; anticancer agents; antidiabetic agents; dietetics |
04/29/2004 | US20040082575 Compounds and methods for modulation of estrogen receptors |
04/29/2004 | US20040082569 Novel substituted amides, their preparation and use |
04/29/2004 | US20040082567 Antiproliferative agents; anticancer agents; fungicides; antiinflammatory agents |
04/29/2004 | US20040082566 Pyrrolidine sulfonamides |
04/29/2004 | US20040082564 Methods for treating metabolic diseases using malonyl-coa decarboxylase inhibitors |
04/29/2004 | US20040082563 Thrombosis therapy; antitumor agents; anticoagulants; Factor x inhibitors; anticholesterol agents; cardiovascular disorders; antiinflammatory agents |
04/29/2004 | US20040082562 Novel inhibitors of IMPDH enzyme |
04/29/2004 | US20040082556 Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use |
04/29/2004 | US20040082555 Use of gaba, inverse agonists in combination with nicotine receptor partial agonist, estrogen, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders |
04/29/2004 | US20040082551 Novel pyrazoles and their use as p38 kinase inhibitors |
04/29/2004 | US20040082550 Tropolone derivative |
04/29/2004 | US20040082548 Cardiovascular disorders; Alzheimer's disease; anticholesterol agents |
04/29/2004 | US20040082547 Prevent thrombosis; anticholesterol agents; cardiovascular disorders; anticancer agents |
04/29/2004 | US20040082542 Useful as modulators of interaction between receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, beta-amyloid and amphoterin |
04/29/2004 | US20040082540 Use of a mixture of sodium hyaluronate and chondroitin sulfate for the treatment of osteoarthritis |
04/29/2004 | US20040082529 Treating or preventing cancer by administering to subject a vector comprising a heterologous polynucleotide operably linked to one or more regulatory sequences derived from an H19, IGF-1 or IGF-2 P4 transcriptional regulatory sequence |
04/29/2004 | US20040082517 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
04/29/2004 | US20040082516 For in vitro/vivo drugs; neuropathy |
04/29/2004 | US20040082512 Drugs for treatment of inflammation/blood brain barrier degradation |
04/29/2004 | US20040082510 Pyk2 phosphorylation by her3 induces tumor invasion |
04/29/2004 | US20040082504 Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
04/29/2004 | US20040082497 For treatment of growth hormone deficiency/polycystic ovary syndrome autoimmune/inflammatory disease |
04/29/2004 | US20040082065 Cascading priming cells; stimulating lymphocytes; incubation |
04/29/2004 | US20040082039 Immunoglobulin fusion proteins |
04/29/2004 | US20040082037 Antiproliferative agents of vascular smooth muscles |
04/29/2004 | US20040082014 Method and test system for identifying substances which protect nerve cells |
04/29/2004 | US20040082009 Compositions and methods for regulating receptor clustering |
04/29/2004 | US20040081984 Ocular tear growth factor-like protein |
04/29/2004 | US20040081971 Gastrointestinal disorders; cardiovascular disorders; autoimmune diseases; cell proliferation; antiinflammatory agents |
04/29/2004 | US20040081714 Cosmetic and/or pharmaceutical preparations |
04/29/2004 | US20040081673 Compositions and methods for the treatment of skin damage |
04/29/2004 | US20040081670 Method for producing an active ingredient concentrate, and an active ingredient concentrate |
04/29/2004 | US20040081665 Chlorella preparations exhibiting immunomodulating properties |